Subtitle
Outcomes of Proton Beam Therapy Compared With Intensity-Modulated Radiation Therapy for Uterine Cancer.
Subtitle
Outcomes of Proton Beam Therapy Compared With Intensity-Modulated Radiation Therapy for Uterine Cancer.
Proto therapy Time
November 2022
Executive summary
This study reported results of patients with uterine cancer treated with PT (n=22) and IMRT (n=45). When comparing gynecologic-specific subset of PRO-CTCAE, PT was associated with less diarrhea at EOT (P = .01) and at 12 months (P = .24) than IMRT. Loss of bowel control at 12 months was more common in patients receiving IMRT (P = .15). Any patient reporting grade 3+ GI toxicity was noted more frequently with IMRT (31% versus 9%, P = .09). The authors concluded that adjuvant PT is a promising treatment for patients with uterine cancer and may reduce patient-reported GI toxicity as compared with IMRT.
Top cancer treatments
Related contents
Proton Therapy Publication
May 2024
Bone Marrow Sparing by Intensity Modulated Proton Beam Therapy in Postoperative Irradiation of Gynecologic Malignancies.
Proton Therapy Publication
May 2023
Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.
Proton Therapy Publication
January 2023
Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial.
Proton Therapy Publication
July and August 2023
Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial.
Proton Therapy Publication
May 2023
Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.